Agomelatine treatment of major depressive disorder in Parkinson's disease: A case series

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 25, Issue 4, 2013, Pages 343-345

  De Berardis, Domenico ^a,b   Fornaro, Michele ^c   Serroni, Nicola ^a   Olivieri, Luigi ^a   Marini, Stefano ^a,b   Moschetta, Francesco Saverio ^a   Srinivasan, Venkataramanujam ^d   Assetta, Maurizio ^a   Valchera, Alessandro ^e   Salone, Anatolia ^b   Martinotti, Giovanni ^b   Onofrj, Marco ^b   Di Giannantonio, Massimo ^b  

^a 'G Mazzini' Hospital   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d Sri Sathya Sai Medical Educational and Research Foundation   (India)

^e Hermanas Hospitalarias   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; DOPAMINE; ESCITALOPRAM; LEVODOPA; NORADRENALIN; PERGOLIDE; SEROTONIN; VENLAFAXINE;

ADULT; ANHEDONIA; ANXIETY DISORDER; AROUSAL; ARTICLE; BEDTIME DOSAGE; CASE REPORT; CASE STUDY; CLINICAL ASSESSMENT TOOL; COMORBIDITY; CONSTIPATION; CRYING; DECREASED APPETITE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; FEMALE; FRONTAL CORTEX; HAMILTON SCALE; HUMAN; HYPERSOMNIA; INSOMNIA; MAJOR DEPRESSION; MALE; MINI MENTAL STATE EXAMINATION; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; REMISSION; SNAITH HAMILTON PLEASURE SCALE; SYMPTOM; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE; WEIGHT REDUCTION; WHITE COLLAR WORKER;

ACETAMIDES; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 84898917693     PISSN: 08950172     EISSN: 15457222     Source Type: Journal    
DOI: 10.1176/appi.neuropsych.12110286     Document Type: Article

References (23)

1. Veazey C, Aki SO, Cook KF, et al: Prevalence and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2005; 17:310-323
2. Weintraub D, Taraborelli D, Morales KH, et al: Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study. J Neuropsychiatry Clin Neurosci 2006; 18:377-383
3. Lauterbach EC, Victoroff J, Coburn KL, et al: Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data. J Neuropsychiatry Clin Neurosci 2010; 22:8-18
4. Fornaro M, Prestia D, Colicchio S, et al: A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol 2010; 8: 287-304
5. De Berardis D, Di Iorio G, Acciavatti T, et al: The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. CNS Neurol Disord Drug Targets 2011; 10:119-132
6. Martinotti G, Sepede G, Gambi F, et al: Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study. J Clin Psychopharmacol 2012; 32:487-491
7. Srinivasan V, Zakaria R, Othman Z, et al: Agomelatine in depressive disorders: its novel mechanisms of action. J Neuropsychiatry Clin Neurosci 2012; 24:290-308
8. Members of the UPDRS Development Committee: Unified Parkinson's Disease Rating Scale in Recent Developments in Parkinson's Disease. Edited by Fahn S, Marsden CD, Calne DB, et al. Florham Park, NJ, Macmillan Health Care Information, 1987
9. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6:278-296
10. Folstein MF, Folstein SE, McHugh PR: "Mini-Mental State:" a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
11. Snaith RP, Hamilton M, Morley S, et al: A scale for the assessment of hedonic tone: the Snaith-Hamilton Pleasure Scale. Br J Psychiatry 1995; 167:99-103
12. European Medicines Agency European Public Assessment Report. Valdoxan, 2012; available at http://www.emea.europa.eu/ ema/index.jsp?curl=pages/medicines/human/medicines/000915/human_ med_001123.jsp&mid=WC0b01ac058001d124; accessed Oct 28, 2012
13. Barone P: Treatment of depressive symptoms in Parkinson's disease. Eur J Neurol 2011; 18(Suppl 1):11-15
14. Meerlo P, Sgoifo A, Turek FW: The effects of social defeat and other stressors on the expression of circadian rhythms. Stress 2002; 5:15-22
15. O'Connor MF, Wellisch DK, Stanton AL, et al: Diurnal cortisol in complicated and non-complicated grief: slope differences across the day. Psychoneuroendocrinology 2012; 37:725-728
16. De Berardis D, Serroni N, Marini S, et al. Agomelatine augmentation of escitalopram therapy in treatment-resistant, obsessive-compulsive disorder: a case report. Case Rep Psychiatry 2012:642752
17. Debonnel G, Saint-André E, Hébert C, et al: Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol 2007; 10:51-61
18. Srinivasan V, De Berardis D, Shillcutt SD, et al: Role of melatonin in mood disorders and the antidepressant effects of agomelatine. Expert Opin Investig Drugs 2012; 21:1503-1522
19. Di Giannantonio M, Di Iorio G, Guglielmo R, et al: Major depressive disorder, anhedonia, and agomelatine: an openlabel study. J Biol Regul Homeost Agents 2011; 25:109-114
20. Di Giannantonio M, Martinotti G: Anhedonia and major depression: the role of agomelatine. Eur Neuropsychopharmacol 2012; 22(Suppl 3):S505-S510
21. 2 receptor expression in Parkinson's disease. Med Sci Monit 2010; 16:BR61-BR67
22. Bruin VM, Bittencourt LR, Tufik S: Sleep-wake disturbances in Parkinson's disease: current evidence regarding diagnostic and therapeutic decisions. Eur Neurol 2012; 67:257-267
23. Suzuki K, Miyamoto T, Miyamoto M, et al: Circadian variation of core body temperature in Parkinson disease patients with depression: a potential biological marker for depression in Parkinson disease. Neuropsychobiology 2007; 56:172-179